ANCA-associated vasculitis trials in China

In China 38 Also abroad 97

38 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2/3Taking people
A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）
Where
Beijing, Hangzhou
Age
18 years and over
People
166
Run by
Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT05979051
No phaseTaking people
(68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis
Where
Shanghai
Age
18 years and over
People
30
Run by
Ruijin Hospital
See details and how to joinNCT07151521
Phase 1Taking people
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Where
Tianjin
Age
18 years and over
People
12
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06941129
Phase 1Not yet taking people in China
The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis
Where
Wuhan
Age
18 years to 60 years
People
12
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07033299
Early phase 1Not yet taking people in China
Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV
Where
Beijing
Age
18 years to 70 years
People
12
Run by
Peking University People's Hospital
See details and how to joinNCT06986018
Phase 1Taking people
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Where
Beijing
Age
18 years to 65 years
People
44
Run by
Beijing GoBroad Hospital
See details and how to joinNCT06980597
Phase 1Not yet taking people in China
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
Where
Changzhou
Age
18 years and over
People
18
Run by
Changzhou No.2 People's Hospital
See details and how to joinNCT06978738
Phase 2Taking people
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Where
Beijing
Age
18 years to 65 years
People
50
Run by
Peking University People's Hospital
See details and how to joinNCT06794008
Early phase 1Not yet taking people in China
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
Where
Wenzhou
Age
18 years to 65 years
People
9
Run by
First Affiliated Hospital of Wenzhou Medical University
See details and how to joinNCT06420154
No phaseTaking people
Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
Where
Wuhan
Age
18 years to 70 years
People
24
Run by
Lingli Dong
See details and how to joinNCT06277427
Phase 4Taking people
Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
Where
Beijing
Age
18 years to 65 years
People
40
Run by
Chinese SLE Treatment And Research Group
See details and how to joinNCT05965284
Phase 4Taking people
Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
Where
Beijing
Age
18 years to 65 years
People
40
Run by
Chinese SLE Treatment And Research Group
See details and how to joinNCT05962840
No phaseTaking people
Multicenter Cohort Study of AAV in Hunan of China
Where
Changsha
People
500
Run by
Xiangya Hospital of Central South University
See details and how to joinNCT05315141